Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...
Cure Today3d
Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...
pharmaphorum4d
Janssen claims FDA okay for would-be Tagrisso rival Rybrevant
like AstraZeneca's market-leading Tagrisso (osimertinib), AZ’s older Iressa (gefitinib) and Roche’s Tarceva (erlotinib). Over time. most targeted cancer drugs have their efficacy limited by ...
EuropaWire6d
AstraZeneca’s Imfinzi Recommended for EU Approval as Breakthrough Treatment for Limited-Stage Small Cell Lung Cancer
AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...
Medscape2d
Clinical Overview of Sorafenib in Breast Cancer
Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with ...